Denali therapeutics announces new data and expansion of its blood-brain barrier (bbb)-crossing enzyme replacement therapy programs at worldsymposium™

South san francisco, calif., feb. 07, 2024 (globe newswire) -- denali therapeutics inc. (nasdaq: dnli), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (bbb) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today announced new data presentations highlighting the broad potential of its bbb-crossing enzyme replacement therapies in development for the treatment of mucopolysaccharidoses (mps). new clinical data on tividenofusp alfa (dnl310) in mps ii (hunter syndrome) and mouse model data on dnl126 (etv:sgsh) in mps iiia (sanfilippo syndrome type a) are being presented this week at the 20th annual worldsymposium™ in san diego, california.
DNLI Ratings Summary
DNLI Quant Ranking